CD95 signaling in colorectal cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 189-198

  Hoogwater, Frederik J H ^a   Steller, Ernst J A ^a   Westendorp, B Florien ^a   Borel Rinkes, Inne H M ^a   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apoptosis; CD95; Colorectal; Invasion; KRAS; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; APO 010; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; K RAS PROTEIN; LIM KINASE 1; NEUTRALIZING ANTIBODY; RAF PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INFILTRATION; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG TARGETING; ENTERITIS; HUMAN; INFLAMMATORY CELL; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD95; COLORECTAL NEOPLASMS; FAS LIGAND PROTEIN; HUMANS; SIGNAL TRANSDUCTION;

EID: 84860321150     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.03.007     Document Type: Review

References (148)

1. Arai H., Gordon D., Nabel E.G., Nabel G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13862-13867.
2. Arai K., Liu Z.X., Lane T., Dennert G. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell. Immunol. 2002, 219:48-56.
3. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26:3621-3630.
4. Backus H.H., Dukers D.F., van Groeningen C.J., Vos W., Bloemena E., Wouters D., van Riel J.M., Smid K., Giaccone G., Pinedo H.M., Peters G.J. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 2001, 12:209-216.
5. Barnhart B.C., Legembre P., Pietras E., Bubici C., Franzoso G., Peter M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004, 23:3175-3185.
6. Bennett M.W., O'Connell J., Houston A., Kelly J., O'Sullivan G.C., Collins J.K., Shanahan F. Fas ligand upregulation is an early event in colonic carcinogenesis. J. Clin. Pathol. 2001, 54:598-604.
7. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., Moonsamy P., Dahlman K., Miller V.A., Costa C., Hannon G., Sawyers C.L. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
8. Borges V.M., Falcao H., Leite-Junior J.H., Alvim L., Teixeira G.P., Russo M., Nobrega A.F., Lopes M.F., Rocco P.M., Davidson W.F., Linden R., Yagita H., Zin W.A., DosReis G.A. Fas ligand triggers pulmonary silicosis. J. Exp. Med. 2001, 194:155-164.
9. Bridgham J.T., Wilder J.A., Hollocher H., Johnson A.L. All in the family: evolutionary and functional relationships among death receptors. Cell Death Differ. 2003, 10:19-25.
10. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., Martin S.J., Force W.R., Lynch D.H., Ware C.F. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373:441-444.
11. + T cell response induced by dendritic cells overexpressing CD95L. J. Leukoc. Biol. 2008, 84:713-720.
12. Buonocore S., Paulart F., Le M.A., Braun M., Salmon I., Van M.S., Thielemans K., Goldman M., Flamand V. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 2003, 101:1469-1476.
13. + T cells and neutrophils expressing XCR1 receptor. J. Immunol. 2001, 167:57-65.
14. Chakrabandhu K., Herincs Z., Huault S., Dost B., Peng L., Conchonaud F., Marguet D., He H.T., Hueber A.O. Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 2007, 26:209-220.
15. Chakrabandhu K., Huault S., Garmy N., Fantini J., Stebe E., Mailfert S., Marguet D., Hueber A.O. The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ. 2008, 15:1824-1837.
16. Chen J., Fujii K., Zhang L., Roberts T., Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7783-7788.
17. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282:1714-1717.
18. Chen L., Park S.M., Tumanov A.V., Hau A., Sawada K., Feig C., Turner J.R., Fu Y.X., Romero I.L., Lengyel E., Peter M.E. CD95 promotes tumour growth. Nature 2010, 465:492-496.
19. Chen L., Park S.M., Turner J.R., Peter M.E. Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond. Inflamm. Bowel. Dis. 2010, 16:1071-1076.
20. Cohen P.L., Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 1991, 9:243-269.
21. Corsini N.S., Sancho-Martinez I., Laudenklos S., Glagow D., Kumar S., Letellier E., Koch P., Teodorczyk M., Kleber S., Klussmann S., Wiestler B., Brustle O., Mueller W., Gieffers C., Hill O., Thiemann M., Seedorf M., Gretz N., Sprengel R., Celikel T., Martin-Villalba A. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009, 5:178-190.
22. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
23. Dan N., Kanai T., Totsuka T., Iiyama R., Yamazaki M., Sawada T., Miyata T., Yagita H., Okumura K., Watanabe M. Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G754-G760.
24. Demjen D., Klussmann S., Kleber S., Zuliani C., Stieltjes B., Metzger C., Hirt U.A., Walczak H., Falk W., Essig M., Edler L., Krammer P.H., Martin-Villalba A. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat. Med. 2004, 10:389-395.
25. Desbarats J., Birge R.B., Mimouni-Rongy M., Weinstein D.E., Palerme J.S., Newell M.K. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 2003, 5:118-125.
26. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 2000, 6:920-923.
27. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373:438-441.
28. Eastwood G.L. Gastrointestinal epithelial renewal. Gastroenterology 1977, 72:962-975.
29. Ehrenreiter K., Piazzolla D., Velamoor V., Sobczak I., Small J.V., Takeda J., Leung T., Baccarini M. Raf-1 regulates Rho signaling and cell migration. J. Cell Biol. 2005, 168:955-964.
30. Eramo A., Sargiacomo M., Ricci-Vitiani L., Todaro M., Stassi G., Messina C.G., Parolini I., Lotti F., Sette G., Peschle C., De M.R. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol. 2004, 34:1930-1940.
31. Ethell D.W., Kinloch R., Green D.R. Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr. Biol. 2002, 12:1595-1600.
32. Fais S., De M.A., Lozupone F. The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 2005, 10:941-947.
33. Faouzi S., Burckhardt B.E., Hanson J.C., Campe C.B., Schrum L.W., Rippe R.A., Maher J.J. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J. Biol. Chem. 2001, 276:49077-49082.
34. Feig C., Tchikov V., Schutze S., Peter M.E. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007, 26:221-231.
35. Fingleton B., Carter K.J., Matrisian L.M. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Cancer Res. 2007, 67:4800-4806.
36. Finnberg N., Kim S.H., Furth E.E., Liu J.J., Russo P., Piccoli D.A., Grimberg A., El-Deiry W.S. Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol. Ther. 2005, 4:937-942.
37. Fischer U., Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005, 12(Suppl. 1):942-961.
38. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Muller C., Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 1996, 133:335-343.
39. Gajate C., Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 2005, 280:11641-11647.
40. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182:1223-1230.
41. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
42. Graf M.R., Prins R.M., Merchant R.E. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J. Immunol. 2001, 166:121-129.
43. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
44. Guicciardi M.E., Gores G.J. Life and death by death receptors. FASEB J. 2009, 23:1625-1637.
45. Guillen-Ahlers H., Suckow M.A., Castellino F.J., Ploplis V.A. Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One 2010, 5:e9070.
46. Guo Z., Zhang M., An H., Chen W., Liu S., Guo J., Yu Y., Cao X. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: different roles of ERK and NF-kappaB signaling pathways. Blood 2003, 102:4441-4447.
47. Guo Z., Zhang M., Tang H., Cao X. Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 2005, 106:2033-2041.
48. Hahne M., Renno T., Schroeter M., Irmler M., French L., Bornard T., MacDonald H.R., Tschopp J. Activated B cells express functional Fas ligand. Eur. J. Immunol. 1996, 26:721-724.
49. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., Settleman J., Giovannini M., Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40:600-608.
50. Hall C.L., Yao M., Hill L.L., Owen-Schaub L.B. Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice. Clin. Exp. Metastasis 2004, 21:251-256.
51. Hohlbaum A.M., Gregory M.S., Ju S.T., Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 2001, 167:6217-6224.
52. Hoogwater F.J., Nijkamp M.W., Smakman N., Steller E.J., Emmink B.L., Westendorp B.F., Raats D.A., Sprick M.R., Schaefer U., van Houdt W.J., de Bruijn M.T., Schackmann R.C., Derksen P.W., Medema J.P., Walczak H., Borel R.I., Kranenburg O. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138:2357-2367.
53. Hoogwater F.J., Snoeren N., Nijkamp M.W., Gunning A.C., van Houdt W.J., de Bruijn M.T., Voest E.E., van H.R., Kranenburg O., Rinkes I.H. Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. Anticancer Res. 2011, 31:4507-4512.
54. Houston A., Bennett M.W., O'Sullivan G.C., Shanahan F., O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br. J. Cancer 2003, 89:1345-1351.
55. Hueber A.O., Bernard A.M., Herincs Z., Couzinet A., He H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep. 2002, 3:190-196.
56. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., Bronson R.T., Mahmood U., Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1565-1570.
57. Huser M., Luckett J., Chiloeches A., Mercer K., Iwobi M., Giblett S., Sun X.M., Brown J., Marais R., Pritchard C. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 2001, 20:1940-1951.
58. Igney F.H., Behrens C.K., Krammer P.H. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int. J. Cancer 2005, 113:78-87.
59. Igney F.H., Krammer P.H. Tumor counterattack: fact or fiction?. Cancer Immunol. Immunother. 2005, 54:1127-1136.
60. Janssen K.P., Alberici P., Fsihi H., Gaspar C., Breukel C., Franken P., Rosty C., Abal M., El Marjou F., Smits R., Louvard D., Fodde R., Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109.
61. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., Stanger B.Z., Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373:444-448.
62. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
63. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
64. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 2000, 10:640-648.
65. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., Thiemann M., Mueller W., Sykora J., Kuhn A., Schreglmann N., Letellier E., Zuliani C., Klussmann S., Teodorczyk M., Grone H.J., Ganten T.M., Sultmann H., Tuttenberg J., von D.A., Regnier-Vigouroux A., Herold-Mende C., Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
66. Kondo T., Suda T., Fukuyama H., Adachi M., Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 1997, 3:409-413.
67. Kreuz S., Siegmund D., Rumpf J.J., Samel D., Leverkus M., Janssen O., Hacker G., ttrich-Breiholz O., Kracht M., Scheurich P., Wajant H. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 2004, 166:369-380.
68. Krueger A., Schmitz I., Baumann S., Krammer P.H., Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 2001, 276:20633-20640.
69. Lavrik I.N., Golks A., Riess D., Bentele M., Eils R., Krammer P.H. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J. Biol. Chem. 2007, 282:13664-13671.
70. Lee K.H., Feig C., Tchikov V., Schickel R., Hallas C., Schutze S., Peter M.E., Chan A.C. The role of receptor internalization in CD95 signaling. EMBO J. 2006, 25:1009-1023.
71. Legembre P., Barnhart B.C., Peter M.E. The relevance of NF-kappaB for CD95 signaling in tumor cells. Cell Cycle 2004, 3:1235-1239.
72. Legembre P., Barnhart B.C., Zheng L., Vijayan S., Straus S.E., Puck J., Dale J.K., Lenardo M., Peter M.E. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep. 2004, 5:1084-1089.
73. Letellier E., Kumar S., Sancho-Martinez I., Krauth S., Funke-Kaiser A., Laudenklos S., Konecki K., Klussmann S., Corsini N.S., Kleber S., Drost N., Neumann A., Levi-Strauss M., Brors B., Gretz N., Edler L., Fischer C., Hill O., Thiemann M., Biglari B., Karray S., Martin-Villalba A. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010, 32:240-252.
74. Li H., Fan X., Stoicov C., Liu J.H., Zubair S., Tsai E., Ste M.R., Wang T.C., Lyle S., Kurt-Jones E., Houghton J. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology 2009, 137:934-944. 944.
75. Lin A., Karin M. NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 2003, 13:107-114.
76. Liu K., Abrams S.I. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J. Immunol. 2003, 170:5973-5980.
77. Liu Z.X., Govindarajan S., Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004, 127:1760-1774.
78. Maecker H.L., Yun Z., Maecker H.T., Giaccia A.J. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002, 2:139-148.
79. Mann B., Gratchev A., Bohm C., Hanski M.L., Foss H.D., Demel G., Trojanek B., Schmidt-Wolf I., Stein H., Riecken E.O., Buhr H.J., Hanski C. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br. J. Cancer 1999, 79:1262-1269.
80. McDermott U., Longley D.B., Galligan L., Allen W., Wilson T., Johnston P.G. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005, 65:8951-8960.
81. Medema J.P., de J.J., van H.T., Melief C.J., Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 1999, 190:1033-1038.
82. Mikula M., Schreiber M., Husak Z., Kucerova L., Ruth J., Wieser R., Zatloukal K., Beug H., Wagner E.F., Baccarini M. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 2001, 20:1952-1962.
83. Miwa K., Asano M., Horai R., Iwakura Y., Nagata S., Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 1998, 4:1287-1292.
84. Miwa K., Hashimoto H., Yatomi T., Nakamura N., Nagata S., Suda T. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int. Immunol. 1999, 11:925-931.
85. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P.H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 1994, 57:371-377.
86. Moller P., Walczak H., Reidl S., Strater J., Krammer P.H. Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia. Am. J. Pathol. 1996, 149:9-13.
87. Montel A.H., Bochan M.R., Hobbs J.A., Lynch D.H., Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 1995, 166:236-246.
88. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 1995, 16:39-43.
89. Nakamoto Y., Kaneko S., Fan H., Momoi T., Tsutsui H., Nakanishi K., Kobayashi K., Suda T. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J. Exp. Med. 2002, 196:1105-1111.
90. Nijkamp M.W., Hoogwater F.J., Steller E.J., Westendorp B.F., van der Meulen T.A., Leenders M.W., Borel R.I., Kranenburg O. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J. Hepatol. 2010, 53:1069-1077.
91. Nozoe T., Yasuda M., Honda M., Inutsuka S., Korenaga D. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003, 65:83-88.
92. O'Connell J., Bennett M.W., Nally K., Houston A., O'Sullivan G.C., Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann. N. Y. Acad. Sci. 2000, 910:178-192.
93. O'Connell J., Bennett M.W., O'Sullivan G.C., Roche D., Kelly J., Collins J.K., Shanahan F. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 1998, 186:240-246.
94. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184:1075-1082.
95. O'Neill E., Rushworth L., Baccarini M., Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004, 306:2267-2270.
96. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
97. Oikonomou E., Kothonidis K., Taoufik E., Probert E., Zografos G., Nasioulas G., Andera L., Pintzas A. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br. J. Cancer 2007, 97:73-84.
98. Ottonello L., Tortolina G., Amelotti M., Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 1999, 162:3601-3606.
99. Owen-Schaub L.B. Fas function and tumor progression: use it and lose it. Cancer Cell 2002, 2:95-96.
100. Owen-Schaub L.B., van Golen K.L., Hill L.L., Price J.E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 1998, 188:1717-1723.
101. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., Deisseroth A.B., Zhang W.W., Kruzel E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 1995, 15:3032-3040.
102. Papenfuss K., Cordier S.M., Walczak H. Death receptors as targets for anti-cancer therapy. J. Cell Mol. Med. 2008, 12:2566-2585.
103. Park D.R., Thomsen A.R., Frevert C.W., Pham U., Skerrett S.J., Kiener P.A., Liles W.C. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J. Immunol. 2003, 170:6209-6216.
104. Park S.M., Chen L., Zhang M., shton-Rickardt P., Turner J.R., Peter M.E. CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm. Bowel. Dis. 2010, 16:1063-1070.
105. Peduto E.L., Guillou L., Saraga E., Schroter M., French L.E., Tschopp J., Juillerat-Jeanneret L. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int. J. Cancer 1999, 81:772-778.
106. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A.O., Newell M.K., Owen L.B., Pope R.M., Tschopp J., Wajant H., Wallach D., Wiltrout R.H., Zornig M., Lynch D.H. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
107. Peter M.E., Legembre P., Barnhart B.C. Does CD95 have tumor promoting activities?. Biochim. Biophys. Acta 2005, 1755:25-36.
108. Piazzolla D., Meissl K., Kucerova L., Rubiolo C., Baccarini M. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J. Cell Biol. 2005, 171:1013-1022.
109. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
110. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
111. Ponton A., Clement M.V., Stamenkovic I. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J. Biol. Chem. 1996, 271:8991-8995.
112. Puliaeva I., Puliaev R., Shustov A., Haas M., Via C.S. Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses. J. Immunol. 2008, 181:5912-5929.
113. + regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death. J. Immunol. 2008, 180:8316-8326.
114. Reed J.C. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 2006, 3:388-398.
115. Reinehr R., Sommerfeld A., Haussinger D. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 2008, 134:1494-1506.
116. Rescigno M., Piguet V., Valzasina B., Lens S., Zubler R., French L., Kindler V., Tschopp J., Ricciardi-Castagnoli P. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 2000, 192:1661-1668.
117. Restifo N.P. Countering the 'counterattack' hypothesis. Nat. Med. 2001, 7:259.
118. Ruan W., Lee C.T., Desbarats J. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell 2008, 19:3192-3202.
119. Russo M., Mupo A., Spagnuolo C., Russo G.L. Exploring death receptor pathways as selective targets in cancer therapy. Biochem. Pharmacol. 2010, 80:674-682.
120. Ryan A.E., Shanahan F., O'Connell J., Houston A.M. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006, 5:246-249.
121. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., Jamieson T.J., Guerra C., Ashton G.H., Barbacid M., Clarke A.R. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14122-14127.
122. Sato T., van Es J.H., Snippert H.J., Stange D.E., Vries R.G., van den B.M., Barker N., Shroyer N.F., van de W.M., Clevers H. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011, 469:415-418.
123. Seidelin J.B., Nielsen O.H. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm. Bowel Dis. 2008, 14:1623-1629.
124. Seino K., Kayagaki N., Okumura K., Yagita H. Antitumor effect of locally produced CD95 ligand. Nat. Med. 1997, 3:165-170.
125. Shimizu M., Fontana A., Takeda Y., Yagita H., Yoshimoto T., Matsuzawa A. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J. Immunol. 1999, 162:7350-7357.
126. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
127. Steller E.J., Borel R.I., Kranenburg O. How CD95 stimulates invasion. Cell Cycle 2011, 10:3857-3862.
128. Steller E.J., Ritsma L., Raats D.A., Hoogwater F.J., Emmink B.L., Govaert K.M., Laoukili J., Borel R.I., van R.J., Kranenburg O. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 2011, 12:931-937.
129. Strater J., Hinz U., Hasel C., Bhanot U., Mechtersheimer G., Lehnert T., Moller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005, 54:661-665.
130. Strater J., Moller P. Expression and function of death receptors and their natural ligands in the intestine. Ann. N. Y. Acad. Sci. 2000, 915:162-170.
131. Strater J., Moller P. CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts. Virchows Arch. 2003, 442:218-225.
132. Strater J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., Krammer P.H., Moller P. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997, 113:160-167.
133. + responder cells by Fas-mediated apoptosis. J. Immunol. 2009, 182:1469-1480.
134. Subauste M.C., Von H.M., Benard V., Chamberlain C.E., Chuang T.H., Chu K., Bokoch G.M., Hahn K.M. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 2000, 275:9725-9733.
135. Tagawa Y., Kakuta S., Iwakura Y. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur. J. Immunol. 1998, 28:4105-4113.
136. Ueyama H., Kiyohara T., Sawada N., Isozaki K., Kitamura S., Kondo S., Miyagawa J., Kanayama S., Shinomura Y., Ishikawa H., Ohtani T., Nezu R., Nagata S., Matsuzawa Y. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998, 43:48-55.
137. Ullrich E., Menard C., Flament C., Terme M., Mignot G., Bonmort M., Plumas J., Chaperot L., Chaput N., Zitvogel L. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev. 2008, 19:79-92.
138. van Geelen C.M., de Vries E.G., de J.S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 2004, 7:345-358.
139. Varadhachary A.S., Edidin M., Hanlon A.M., Peter M.E., Krammer P.H., Salgame P. Phosphatidylinositol 3'-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J. Immunol. 2001, 166:6564-6569.
140. Verbrugge I., Wissink E.H., Rooswinkel R.W., Jongsma J., Beltraminelli N., Dupuis M., Borst J., Verheij M. Combining radiotherapy with APO010 in cancer treatment. Clin. Cancer Res. 2009, 15:2031-2038.
141. von P.A., Bastmeyer M. Mechanisms of gradient detection: a comparison of axon pathfinding with eukaryotic cell migration. Int. Rev. Cytol. 2007, 263:1-62.
142. Whiteside T.L. The role of death receptor ligands in shaping tumor microenvironment. Immunol. Invest. 2007, 36:25-46.
143. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
144. Xu Y., Szalai A.J., Zhou T., Zinn K.R., Chaudhuri T.R., Li X., Koopman W.J., Kimberly R.P. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 2003, 171:562-568.
145. Yao H., Song E., Chen J., Hamar P. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br. J. Cancer 2004, 91:1718-1725.
146. Yoong K.F., Afford S.C., Randhawa S., Hubscher S.G., Adams D.H. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 1999, 154:693-703.
147. Zang F., Sun B., Zhao X., Niu R., Zhang S., Yu M., Wei X., Zhang L. Critical role for c-FLIP(L) on Fas resistance in colon carcinoma cell line HT-29. Cell Biol. Int. 2008, 32:329-336.
148. Zuliani C., Kleber S., Klussmann S., Wenger T., Kenzelmann M., Schreglmann N., Martinez A., del Rio J.A., Soriano E., Vodrazka P., Kuner R., Groene H.J., Herr I., Krammer P.H., Martin-Villalba A. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ. 2006, 13:31-40.